Ideas
Buy Korean semis on dips.
January is the semiconductor earnings season; Samsung Electronics and SK hynix results should confirm strong demand and shortages, while the main risk is supply from inheritance-tax block sales or large new semiconductor listings. Since earnings are intact, price dips in Korean semiconductors are buying opportunities.
Robotics is a return-hunting theme.
Late-January return-hunting should rotate among robots, bio, and space/aerospace; robotics is a core high-beta theme with continuing catalysts from Boston Dynamics and Hyundai Motor.
Space and defense have February catalyst.
US policy-driven capex and the Artemis catalyst should keep space, aerospace, and defense in the return-hunting rotation, especially into the February event window.
February favors Korean bio.
February is the bio momentum month: JPM healthcare, China containment, KOSDAQ support policies, bio industry promotion, and faster drug approvals should support Korean bio and healthcare.
March holding companies face reform catalysts.
March shareholder-meeting season should force large groups and holding or intermediate holding companies to address governance reform, shareholder returns, and restructuring. Named catalysts include Samsung C&T and Samsung Life, Hyundai Mobis, Hyundai Glovis's Boston Dynamics stake, SK Square's SK hynix stake, Korea Shipbuilding's HD Hyundai Heavy stake, and Hanwha's governance.
KOSPI likely breaks 5,000 milestone.
KOSPI is likely to challenge and break 5,000, but near that milestone the better strategy is individual-stock and thematic stock selection rather than simply holding the index, because return-hunting is moving into specific sectors and names.
Korea Aerospace has record cycle.
Korea Aerospace Industries is a known quality name in an unprecedented aerospace cycle, and its recent surge shows funds rotating into individual high-return names ahead of the 5,000 index level and Artemis.
Large-cap value beats small caps.
With rates still high and policy/industrial transformation driving capex, growth themes are lifting large-cap value and cyclical stocks rather than hyper-valued small caps; bond money and retail deposits rotating into equities favor familiar large caps, so even KOSDAQ momentum should favor top market-cap names over small caps.
Large-cap value beats small caps.
With rates still high and policy/industrial transformation driving capex, growth themes are lifting large-cap value and cyclical stocks rather than hyper-valued small caps; bond money and retail deposits rotating into equities favor familiar large caps, so even KOSDAQ momentum should favor top market-cap names over small caps.
KOSDAQ benefits from Q1 policy.
Korea's Q1 policy calendar includes KOSDAQ competitiveness measures, pension benchmark changes, venture fund tax breaks, and bio-industry support; if policy is the driver, KOSDAQ is the main venue.
Defense satellites gain from Golden Dome.
Golden Dome and Greenland missile-defense needs will require military satellites, and Korean satellite and defense suppliers could benefit.
Korean shipbuilders win special-vessel demand.
Arctic routes and Golden Dome needs should lift icebreaker and special-vessel demand; Korean shipbuilders, especially HD Hyundai Heavy Industries and Samsung Heavy Industries, have high order outlooks as special and LNG vessels exceed half of 2026 orders.
Hyundai Motor leads robot value chain.
Boston Dynamics' next-generation Atlas and Hyundai Motor's 2028 30k-unit plan make the Hyundai Motor value chain the first place to look for robot suppliers; existing auto vendors can supply actuators, ball screws, and assembly, so Hyundai Motor and its suppliers should benefit before other robot stocks.
Samsung Biologics wins CDMO orders.
US containment of Chinese biotech via the BIOSECURE Act should push pharma outsourcing away from China; Samsung Biologics is Korea's largest CDMO and its product and order count is rising, with 200-300 orders as a key re-rating trigger.
HYBE gains from BTS comeback.
BTS's comeback schedule has expanded to around 80 concerts with high ticket prices and mostly US dates, potentially generating about 1.5-2 trillion won in concert revenue plus goods; HYBE's annual revenue is around 2 trillion won, so quarterly revenue could double and Weverse engagement may rise. The market may be underestimating this.
Medical tourism and beauty devices rise.
Tourism data show growth despite flat visitor numbers, with skin and beauty and medical shopping reaching 60% of consumption; beauty medical device exports and cash-rich tourism and medical companies could support earnings and future shareholder returns.
This 3PRO TV (삼프로TV) video, published January 19, 2026,
features Lee Hyuk-jin
discussing 005930.KS, 000660.KS, Korean Semiconductors, Korean Robotics, ITA, SPACE, Korean bio/healthcare, 028260.KS, 032830.KS, 012330.KS, 086280.KS, 402340.KS, 009540.KS, 000880.KS, Korean holding companies, EWY, 047810.KS, Korean large-cap value stocks, Korean small-cap stocks, KOSDAQ, Defense satellites, 329180.KS, 010140.KS, Korean shipbuilders, 005380.KS, 207940.KS, 352820.KS, Korean medical tourism, Aesthetic medical devices.
16 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Lee Hyuk-jin
· Tickers:
005930.KS,
000660.KS,
Korean Semiconductors,
Korean Robotics,
ITA,
SPACE,
Korean bio/healthcare,
028260.KS,
032830.KS,
012330.KS,
086280.KS,
402340.KS,
009540.KS,
000880.KS,
Korean holding companies,
EWY,
047810.KS,
Korean large-cap value stocks,
Korean small-cap stocks,
KOSDAQ,
Defense satellites,
329180.KS,
010140.KS,
Korean shipbuilders,
005380.KS,
207940.KS,
352820.KS,
Korean medical tourism,
Aesthetic medical devices
